In recent years, GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) have become immensely popular due to their proven effectiveness in promoting weight loss and managing type 2 diabetes. However, despite their appeal as a revolutionary solution, it is crucial to recognize that these medications carry significant risks, particularly for individuals contemplating long-term use or... Continue Reading →